Steps to complete the survey:
1. Click on Sign In button and login using Mobile or Email OTP
2. Now, click on Participate button
3. Watch the entire video
4. Once the video ends, you will be redirected to the survey page
5. Fill in the survey and submit
6. Please fill out the bank details after submitting the survey
Lowering of low-density lipoprotein cholesterol (LDL-C) with statins reduces the risk of atherosclerotic cardiovascular disease (ASCVD) and associated mortality proportionally to the absolute decrease in LDL-C. The risk of major cardiovascular events is reduced by 22% for every 1-mmol/L (38.7-mg/dL) reduction in LDL-C.
Up to 80% of the patients do not achieve optimal LDL-C levels with statins, because of high- baseline LDL-C levels, aggressive LDL-treatment goals, or poor statin adherence, often related to adverse drug reactions. These patients may benefit from additional LDL-C lowering therapies. The survey is intended to gather opinions from renowned cardiologists regarding the use of ongoing statin therapies and selection of patient profiles for additional LDL-C lowering therapies to achieve best treatment outcomes in patients with or at risk of atherosclerotic cardiovascular disease.
Target Audience:
Cardiologists
Objectives:
1. To analyze additional LDL-C lowering therapies for patients who do not achieve sufficient LDL-C lowering with statin monotherapy.
2. To derive an unbiased approach in decision making and appropriate selection of patient profile for better LDL-C control.
3. To analyze results obtained from the survey and to address the topic of importance.